Cyclopamine

For research use only.

Catalog No.S1146 Synonyms: 11-deoxojervine

47 publications

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cyclopamine has been cited by 47 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NYXRfpdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTVwOE[2OkDPxE1? M{L5UHNCVkeHUh?=
DOHH-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETzUG9KSzVyPUmuN|U3QDlizszN MWHTRW5ITVJ?
no-10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTlwOUCzPUDPxE1? NHznc5pUSU6JRWK=
LS-513 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;RTWM2OD1zMT6zOVQ4KM7:TR?= NF:z[4ZUSU6JRWK=
ALL-PO MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjyTWM2OD1zMT63O|M1KM7:TR?= M1nr[3NCVkeHUh?=
8-MG-BA MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7DZlNXUUN3ME2xN{4yOTJ|IN88US=> M3vJdHNCVkeHUh?=
RPMI-8402 M{PI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O5NWlEPTB;MUWuPFU{PyEQvF2= MnnBV2FPT0WU
EoL-1-cell M3zQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF6LkW5OFgh|ryP NFy4U4xUSU6JRWK=
NALM-6 NGewNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3De5JKSzVyPUG5MlAyPjdizszN MlHNV2FPT0WU
DEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP0SXFKSzVyPUKwMlE1PzFizszN NFjjRoxUSU6JRWK=
SR MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ|Lk[3NVUh|ryP NV3iNZVvW0GQR1XS
697 NV7sW|hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;EPWlEPTB;Mk[uOlE2PSEQvF2= MoTYV2FPT0WU
COLO-829 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i1XmlEPTB;Mk[uPFQ5OyEQvF2= M4PkcXNCVkeHUh?=
EVSA-T MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[1OGlEPTB;MkeuOVU3OSEQvF2= MYXTRW5ITVJ?
ATN-1 NFLTU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jIS2lEPTB;M{GuNlMzQSEQvF2= NF\qd3JUSU6JRWK=
L-363 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrUcWMyUUN3ME2zNU44PDZzIN88US=> M2LWUHNCVkeHUh?=
LAMA-84 NXvQZoh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fWZWlEPTB;M{KuOVIyOSEQvF2= Mo[yV2FPT0WU
NOS-1 NXvtSWV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnhVY91UUN3ME2zOE4zQTV4IN88US=> NUL6[3JPW0GQR1XS
BB30-HNC Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLjWGVCUUN3ME2zOE4{OzB4IN88US=> NWLDZ5RDW0GQR1XS
BC-1 MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrEfJFKSzVyPUO3Mlk4PDZizszN NHrn[ZVUSU6JRWK=
IST-SL2 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYizTHFpUUN3ME2zPE4zOjRizszN NW\YUHhXW0GQR1XS
D-392MG NXPzeGo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PNSWlEPTB;NECuNlIyPSEQvF2= M{GxOXNCVkeHUh?=
no-11 Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLo[ndvUUN3ME20NE42PTJzIN88US=> NFTienBUSU6JRWK=
LC4-1 NX\wfVNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\uWlZuUUN3ME20NE45PzF4IN88US=> M4nIXnNCVkeHUh?=
A388 M2PaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD5eZpKUUN3ME20Nk42QDR6IN88US=> MoftV2FPT0WU
NTERA-S-cl-D1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR{LkewO|Qh|ryP Mom3V2FPT0WU
CESS M364TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTR2LkKyN|Ih|ryP MlfBV2FPT0WU
RS4-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHJcYZKSzVyPUS5MlA6OzhizszN MVHTRW5ITVJ?
MS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HIdGlEPTB;NUCuPVM2OSEQvF2= Mm\lV2FPT0WU
CTV-1 M{XmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17KZmlEPTB;NUGuNFc1KM7:TR?= M3fDOXNCVkeHUh?=
D-502MG M2K5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTVzLk[yO|Eh|ryP NF3pV2NUSU6JRWK=
ML-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTV{LkmxPVUh|ryP Ml\hV2FPT0WU
SK-NEP-1 NUKwcpdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn5U25KSzVyPUWzMlM6OjNizszN MnfZV2FPT0WU
LOXIMVI M3r4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv4TlIxUUN3ME21N{42QDh2IN88US=> MXzTRW5ITVJ?
DJM-1 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTV4LkOzPVEh|ryP MYLTRW5ITVJ?
GI-1 NGfMPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13USGlEPTB;NU[uOlE1QSEQvF2= MVnTRW5ITVJ?
IST-MES1 NVzn[II4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTZyLkW0PVMh|ryP NEXJSJRUSU6JRWK=
MV-4-11 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfkbnJKSzVyPU[wMlY2OzhizszN NFjIb|hUSU6JRWK=
OVCAR-4 NEKydY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL0TWM2OD14Mz61OlU4KM7:TR?= NVG2c5dTW0GQR1XS
KE-37 NHjBdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P6XmlEPTB;Nk[uNlY3QCEQvF2= NWDVbYRRW0GQR1XS
D-542MG M2HXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n0[mlEPTB;NkiuOFE{PSEQvF2= NV;OXXQ5W0GQR1XS
MHH-PREB-1 NFHxcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLwTWM2OD15Mj64OFQyKM7:TR?= M3H1U3NCVkeHUh?=
MRK-nu-1 M3G5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHRWY5KSzVyPUezMlQ4ODVizszN MWrTRW5ITVJ?
D-247MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnmPFluUUN3ME23N{42PDR{IN88US=> MUHTRW5ITVJ?
OCI-AML2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTd4LkmzOlkh|ryP NHXab3FUSU6JRWK=
LP-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;QcWdUUUN3ME24Nk45PzNzIN88US=> NVnlcFBOW0GQR1XS
HCC1599 NFn1XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK2NoVKSzVyPUi0MlI5OzdizszN NYDWbWx6W0GQR1XS
KARPAS-45 NWjKO4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PUdmlEPTB;OESuOlk6OiEQvF2= MWLTRW5ITVJ?
BE-13 NYnBe29sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPXPFVYUUN3ME25PU4xPDd5IN88US=> NVG1cpc2W0GQR1XS
GCIY M{DBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInHeWpKSzVyPUm5MlA6PTRizszN MlXEV2FPT0WU
BV-173 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HCSGlEPTB;MUCwMlMzPSEQvF2= NVLXb21GW0GQR1XS
LB2518-MEL NIHuRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37DUmlEPTB;MUCwMlc5QSEQvF2= MVXTRW5ITVJ?
KS-1 M4XQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\MVVlIUUN3ME2xNFEvPjN7IN88US=> MULTRW5ITVJ?
MOLT-16 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFyND65PFYh|ryP NFjhNndUSU6JRWK=
NCI-H1770 M{PEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrTXmcxUUN3ME2xNFgvPzh2IN88US=> NWPW[|RqW0GQR1XS
NCI-H82 NVrOeVQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TSNmlEPTB;MUGwMlk4PiEQvF2= Mk\FV2FPT0WU
NCCIT NXXjUolST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTw[ZZKSzVyPUGxNk42OjlizszN MXrTRW5ITVJ?
KALS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml36TWM2OD1zMUWuPVQyKM7:TR?= NHHrWGpUSU6JRWK=
LB2241-RCC NWLkeWpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHrRo9KSzVyPUGxOk43PzlizszN NWPaXHA6W0GQR1XS
HH M13aSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKwcnhKSzVyPUGxO{4{QTVizszN NXnWRXRjW0GQR1XS
HD-MY-Z NYXWeotWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nrZ2lEPTB;MUG4MlQ5QCEQvF2= MkD4V2FPT0WU
EB-3 M{fUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF{Mz6wPVQh|ryP M4Xo[HNCVkeHUh?=
BL-70 NIjINmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjrT2JKSzVyPUGyN{4yOjdizszN Mn\hV2FPT0WU
K-562 NW\4bYtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2yVYFKSzVyPUGyOk4zPDVizszN NHPtZolUSU6JRWK=
HT-144 NFXrTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF|Mz6xOlQh|ryP M4fo[HNCVkeHUh?=
PF-382 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELK[GJKSzVyPUGzOE4{PjFizszN MVfTRW5ITVJ?
RPMI-8226 NInNS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr3OYpnUUN3ME2xN|UvODR3IN88US=> M3i1TnNCVkeHUh?=
NCI-H1355 M3GxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni1TWM2OD1zM{WuOVg4KM7:TR?= M2m2eHNCVkeHUh?=
LXF-289 M1W4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF|OT63PFEh|ryP NIHDcWRUSU6JRWK=
NCI-H69 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK1TWM2OD1zNEKuPVMzKM7:TR?= NWnCclE5W0GQR1XS
SK-MEL-1 NX6zO2dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETn[nhKSzVyPUG0O{4yOyEQvF2= NGnZSYdUSU6JRWK=
KARPAS-299 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLCPIpKSzVyPUG0PU4yOiEQvF2= MY\TRW5ITVJ?
GB-1 NEDHSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7aO5pKSzVyPUG0PU4{OjJizszN MYfTRW5ITVJ?
CMK NEXadWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOwTWM2OD1zNEmuOVE2KM7:TR?= Mlv1V2FPT0WU
MPP-89 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjEe3BnUUN3ME2xOVYvODN3IN88US=> M3znb3NCVkeHUh?=
KU812 NVzNclFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF4MT65NFIh|ryP NEXhVGxUSU6JRWK=
REH M3y2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Oz[mlEPTB;MU[yMlEzPSEQvF2= MUDTRW5ITVJ?
NEC8 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF4NT6wNlYh|ryP NEf1UJVUSU6JRWK=
KP-N-YS NXS1bIt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHpb4dKSzVyPUG2PE4{QTVizszN MYXTRW5ITVJ?
Ramos-2G6-4C10 NFW4dGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO1THluUUN3ME2xOlkvQTF3IN88US=> Ml[3V2FPT0WU
Becker NIrJd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLETWM2OD1zN{SuNVgh|ryP Ml7tV2FPT0WU
LB647-SCLC M2O2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF5NT64OFUh|ryP MUPTRW5ITVJ?
LU-139 M4fkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDq[lhKSzVyPUG3PE4xOTlizszN NHLMWodUSU6JRWK=
QIMR-WIL MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXrbFN4UUN3ME2xO|kvPjR4IN88US=> NYrHWmYxW0GQR1XS
NCI-H1395 NYrSToI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[2TlZNUUN3ME2xO|kvQTl4IN88US=> Mnm5V2FPT0WU
NOMO-1 M3HIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDaNJVKSzVyPUG4Nk45PSEQvF2= MU\TRW5ITVJ?
GI-ME-N MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF6Nz65Olkh|ryP NIr4WHFUSU6JRWK=
KMS-12-PE NYH6dGV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHtUldKSzVyPUG4PU4zPzNizszN NVzQellFW0GQR1XS
Daudi M4ny[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DPVmlEPTB;MUmxMlEzQCEQvF2= MojVV2FPT0WU
LB996-RCC MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF7MT62PVkh|ryP M3r0dnNCVkeHUh?=
NCI-H2107 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF7Mz63N|kh|ryP MWnTRW5ITVJ?
SK-PN-DW Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF7ND63NVkh|ryP MoDOV2FPT0WU
MC-CAR NWrwSYV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXkdIJKSzVyPUKwNk4zPTNizszN NGXKS4pUSU6JRWK=
SNB75 M{DlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnzfFFiUUN3ME2yNlEvQTRizszN M{TMe3NCVkeHUh?=
ES4 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETtd5hKSzVyPUKyN{44QDNizszN MmHmV2FPT0WU
KARPAS-422 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPnflhQUUN3ME2yNlgvOzV{IN88US=> NICwUXZUSU6JRWK=
NCI-H1648 MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXPcYhZUUN3ME2yNlkvPDh7IN88US=> MVrTRW5ITVJ?
ES6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjkTWM2OD1{M{muOFMh|ryP NGHTTGFUSU6JRWK=
KNS-81-FD NXvpVHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j4XGlEPTB;MkSxMlE6PyEQvF2= NHXSd3hUSU6JRWK=
JAR NHPKe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPU[ZBMUUN3ME2yOVYvOjJ3IN88US=> MoPkV2FPT0WU
NB1 NXS4[WRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXBTWM2OD1{NkCuOVE3KM7:TR?= M4q3eHNCVkeHUh?=
D-336MG NHrkRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\2U2lEPTB;Mk[wMlY6QCEQvF2= M3LKUXNCVkeHUh?=
BC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ4NT6xO|gh|ryP M4ntZXNCVkeHUh?=
HCC2218 M1yy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjOOYkyUUN3ME2yOlYvPDF3IN88US=> M4nCVnNCVkeHUh?=
TE-9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDJTZhKSzVyPUK2Ok43OjdizszN MoPXV2FPT0WU
LB1047-RCC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP4VlgxUUN3ME2yOlYvPzV|IN88US=> Ml\vV2FPT0WU
CTB-1 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWwSoYzUUN3ME2yOlkvQTd|IN88US=> MXnTRW5ITVJ?
NB7 NXzZdJZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nOPGlEPTB;MkexJO69VQ>? NFPxOY9USU6JRWK=
ST486 NFLKVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOzTWM2OD1{N{euOFEzKM7:TR?= Mnq1V2FPT0WU
HCC1187 NXWzcpFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jKV2lEPTB;MkiyMlgyOSEQvF2= MWXTRW5ITVJ?
NCI-SNU-16 NVvKZ3VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX3TWM2OD1{OESuNlQ5KM7:TR?= M3\OXXNCVkeHUh?=
COR-L279 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLuTWM2OD1{OUGuOVg1KM7:TR?= NInNR5JUSU6JRWK=
ES8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPMTldjUUN3ME2yPVQvOTh{IN88US=> NV7sS5M3W0GQR1XS
U-698-M MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i0TGlEPTB;Mkm4MlI1OyEQvF2= MYLTRW5ITVJ?
HEL NYTDWZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTNyOT6xOFkh|ryP MX7TRW5ITVJ?
KINGS-1 NIDGVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjETWVKSzVyPUOxNE43PzRizszN NX7wT3R{W0GQR1XS
KY821 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHlTWM2OD1|M{[uOVk2KM7:TR?= M1XTZ3NCVkeHUh?=
MZ1-PC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO3TWM2OD1|NEWuOlE5KM7:TR?= NUnVeG0{W0GQR1XS
LS-411N NUK3flhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\DNJJKSzVyPUO1OE43PiEQvF2= NUTJ[HE6W0GQR1XS
SIG-M5 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL6TWM2OD1|NUmuO|gzKM7:TR?= M{\sfnNCVkeHUh?=
HT MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ETWM2OD1|NkeuO|EyKM7:TR?= Mm\lV2FPT0WU
HC-1 NXywOmxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG1TWM2OD1|NkeuO|g4KM7:TR?= MXrTRW5ITVJ?
NCI-H1694 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLleoFKSzVyPUO3Nk46OzRizszN MVzTRW5ITVJ?
BB65-RCC NWHpcZRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PSe2lEPTB;M{e2MlI1PSEQvF2= NGjhXoNUSU6JRWK=
HAL-01 NEfN[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN5OT64N|gh|ryP NFvlNG9USU6JRWK=
ARH-77 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;tTphKSzVyPUO5OE4xODhizszN Ml\lV2FPT0WU
MZ7-mel MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP3TWM2OD1|OUeuNlM{KM7:TR?= NIrLOIVUSU6JRWK=
SIMA NW\KSllVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMZ3R1UUN3ME20NFMvQTN|IN88US=> NXTEdoZQW0GQR1XS
DG-75 M2HkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTGS4dFUUN3ME20NVUvPjl6IN88US=> M{PiVXNCVkeHUh?=
HUTU-80 M1HReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[0epozUUN3ME20NVkvOTh3IN88US=> NIfkflFUSU6JRWK=
KNS-42 NIP0XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTMTWM2OD12MkWuPFE2KM7:TR?= NGDMeYVUSU6JRWK=
SH-4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR{Nz61OlUh|ryP M1fiUHNCVkeHUh?=
L-540 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PmVGlEPTB;NEOxMlA{OSEQvF2= NF\LVGVUSU6JRWK=
NB10 NVXhOWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXDTGFXUUN3ME20OFEvOjN2IN88US=> NITCNXlUSU6JRWK=
ES1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnMdmJUUUN3ME20OVIvPzV|IN88US=> MXrTRW5ITVJ?
KMOE-2 M1fSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy5b5BKSzVyPUS1Ok44OTFizszN M3\y[XNCVkeHUh?=
MC116 MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3tTWM2OD12NUiuNVE3KM7:TR?= M{D1SnNCVkeHUh?=
RCC10RGB Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PiOGlEPTB;NE[wMlAxPSEQvF2= NXvZcpVYW0GQR1XS
RL95-2 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr6TWM2OD12NkCuNlM4KM7:TR?= MlTmV2FPT0WU
Raji MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzYN25YUUN3ME20OlgvOTR|IN88US=> NF:2[XpUSU6JRWK=
CAS-1 M4TqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLYfI9KSzVyPUS3Nk4xPzNizszN MmjzV2FPT0WU
Calu-6 NX3XRXJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrNOIFUUUN3ME20O|UvOjZ3IN88US=> NXG2WXBtW0GQR1XS
KG-1 M2e1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTR5OD60OEDPxE1? NUnJS2VYW0GQR1XS
LB771-HNC M37yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDYNm9KSzVyPUS4Nk4zOzJizszN M{XUSHNCVkeHUh?=
ACN NXLve2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTybWVKSzVyPUS5N{42QTlizszN NWXDXHNuW0GQR1XS
KM12 NG\yOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfVU|NKSzVyPUS5Ok42QDlizszN M3Ptb3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
NF-κB / Cyclin D1 / MMP2 / MMP9; 

PubMed: 23599805     


Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. 

Gli1 / TGF-β1 / CXCR4; 

PubMed: 26137001     


Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h.

Snail / E-cadherin / Slug / Vimentin ; 

PubMed: 26859575     


SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.

23599805 26137001 26859575
Immunofluorescence
Vimentin; 

PubMed: 24553082     


Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.

PCNA / β-catenin; 

PubMed: 28747625     


Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.

24553082 28747625
In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
- Collapse

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
- Collapse
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine|Cyclopamine ic50|Cyclopamine price|Cyclopamine cost|Cyclopamine solubility dmso|Cyclopamine purchase|Cyclopamine manufacturer|Cyclopamine research buy|Cyclopamine order|Cyclopamine mouse|Cyclopamine chemical structure|Cyclopamine mw|Cyclopamine molecular weight|Cyclopamine datasheet|Cyclopamine supplier|Cyclopamine in vitro|Cyclopamine cell line|Cyclopamine concentration|Cyclopamine nmr|Cyclopamine in vivo|Cyclopamine clinical trial|Cyclopamine inhibitor|Cyclopamine Stem Cells & Wnt inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID